Potential Therapeutic Targets for Cardiac Fibrosis
- 11 June 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 106 (11), 1675-1680
- https://doi.org/10.1161/circresaha.110.217737
Abstract
Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. During connective tissue repair, “activated” fibroblasts migrate into the wound area, where they synthesize and remodel newly created extracellular matrix. The specialized type of fibroblast responsible for this action is the α-smooth muscle actin (α-SMA)–expressing myofibroblast. Abnormal persistence of the myofibroblast is a hallmark of fibrotic diseases. Proteins such as transforming growth factor (TGF)β, endothelin-1, angiotensin II (Ang II), connective tissue growth factor (CCN2/CTGF), and platelet-derived growth factor (PDGF) appear to act in a network that contributes to myofibroblast differentiation and persistence. Drugs targeting these proteins are currently under consideration as antifibrotic treatments. This review summarizes recent observations concerning the contribution of TGFβ, endothelin-1, Ang II, CCN2, and PDGF and to fibroblast activation in tissue repair and fibrosis and the potential utility of agents blocking these proteins in affecting the outcome of cardiac fibrosis.Keywords
This publication has 67 references indexed in Scilit:
- Cardiac mast cells cause atrial fibrillation through PDGF-A–mediated fibrosis in pressure-overloaded mouse heartsJCI Insight, 2010
- Connective Tissue Growth Factor Overexpression in Cardiomyocytes Promotes Cardiac Hypertrophy and Protection against Pressure OverloadPLOS ONE, 2009
- Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivoJournal of Cell Communication and Signaling, 2009
- Connective tissue growth factor promoter activity in normal and wounded skinFibrogenesis & Tissue Repair, 2008
- Interleukin-13 Protects Against Experimental Autoimmune Myocarditis by Regulating Macrophage DifferentiationThe American Journal of Pathology, 2008
- TGF-β1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathwaysAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- The Myofibroblast: One Function, Multiple OriginsThe American Journal of Pathology, 2007
- FAK Is Required for TGFβ-induced JNK Phosphorylation in Fibroblasts: Implications for Acquisition of a Matrix-remodeling PhenotypeMolecular Biology of the Cell, 2007
- Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B ReceptorsMolecular and Cellular Biology, 2006
- Accelerated Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-βScience, 1987